VBL Therapeutics jumps on 'fast track' tag for cancer therapy

Notable Labs

26/04/2022 13:40

** Shares of drug developer  VBLT.O  rise ~12.4% to $1.63
premarket
    ** Co says U.S. FDA has granted 'fast track' designation to
its experimental therapy, ofra-vec, in combination with
chemotherapy medication paclitaxel for treatment of ovarian
cancer  urn:newsml:reuters.com:*:nGNX34BfLM
    ** The tag is intended to speed up development and review of
therapeutics intended to treat serious or life-threatening
conditions
    ** Progression free survival data from an ongoing late-stage
study for ofra-vec is expected in H2 of 2022
    ** VBLT anticipates submitting marketing application in H1
2023
    ** As of last close, stock had fallen 26.40% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))